Sun Pharma Secures SAHPRA Approval to Manufacture Generic Semaglutide in South Africa
Sun Pharmaceutical Industries Limited has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection within South Africa. The medication is intended for treating adults with inadequately controlled type 2 diabetes mellitus, serving as an adjunct to diet and exercise.The company plans to launch the product in the coming days. It will be available as a pre-filled, multi-dose injectable pen designed for flexible, once-weekly dosing.
Sun Pharma stated that South Africa represents the second market, following India, where the company has received approval for generic semaglutide. This development highlights Sun Pharma's capability to develop complex generic medicines that comply with stringent quality standards across diverse global markets.
The availability of this medication is positioned as a significant step toward improving access to generics and providing evidence-based treatment options for patients and healthcare professionals.
South Africa faces challenges related to the rising prevalence of type 2 diabetes, a trend driven in part by rapid urbanization and changing lifestyles, which places considerable pressure on both patients and health services. Providing improved access to effective therapies is crucial in addressing this national health concern.
Product Details
The generic semaglutide injection will be available in two different strengths:| Strength | Packaging | Dosing Frequency |
|---|---|---|
| 2 mg/1.5 mL | Pre-filled, multi-dose pen | Once-weekly |
| 4 mg/3 mL | Pre-filled, multi-dose pen | Once-weekly |
Aalok Shanghvi, Chief Operating Officer at Sun Pharma, emphasized that this approval underscores the company's ability to develop complex generic medicines. He noted that the firm remains committed to making treatment options accessible to patients and healthcare professionals globally.
SUNPHARMA Stock Price Movement
Sun Pharmaceutical Industries Limited shares gained on Tuesday, climbing 1.22% and closing at ₹1942.60 after showing solid buying pressure throughout the trading session. The stock demonstrated strong conviction, staying within a tight intraday range while maintaining proximity to its 52-week high of ₹1953.9.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.